Industry Focus
Healthcare: Is It (Finally) OK To Buy Valeant and Gilead Sciences Again?
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:23:44
- Mas informaciones
Informações:
Sinopsis
We dig into Valeant and Gilead Sciences' first quarter financials to see if shares are a bargain, or a bust. Thanks to Slack for supporting The Motley Fool. Learn more at slack.com.
